.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median consequence of 11 months, people along with metastatic stomach lumps that obtained biomarker-matched therapies based upon circulating lump DNA profiling showed a better medical advantage than those acquiring unequaled therapy.